Actively Recruiting
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
Led by Sun Yat-sen University · Updated on 2024-09-27
24
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma. Researchers will observe the toxicity response of patients receiving nab-paclitaxel at 180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m².
CONDITIONS
Official Title
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed nasopharyngeal carcinoma
- Stage III-IVa disease (AJCC 8th edition)
- Age between 18 and 70 years
- Performance status score of 0 or 1
- Normal organ functions to tolerate chemotherapy and radiotherapy
You will not qualify if you...
- Other cancers within the past 5 years except carcinoma in situ, treated non-melanoma skin cancer, or papillary thyroid cancer
- Symptomatic heart failure or unstable angina
- Recent myocardial infarction
- Active infections needing systemic therapy
- Psychiatric disorders or social/family factors limiting participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
F
Fang-Yun Xie
CONTACT
P
Pu-Yun OuYang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here